Dyne Therapeutics to present preclinical DMD data at NMSG meeting
Dyne Therapeutics plans to present preclinical data for multiple DMD candidates at the 27th Annual NMSG Scientific Meeting. The data support four investigational therapies targeting exon skipping 53, 45, 44 or 55, advancing into IND-enabling studies.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.